Kopran, a company in the Pharmaceuticals industry, reported revenue of ₹211 crore and net profit of ₹4.39 crore for the September 2026 quarter.
Kopran (NSE: KOPRAN) closed at ₹263.16 on 20 Nov 2026, up 96.4% over the past year. Its market capitalisation is ₹1,272 crore and it trades at 32.4 times earnings.
Kopran Ltd. is a fully integrated pharmaceutical company that manufactures and supplies high-quality formulations and active pharmaceutical ingredients globally.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.